You are here:  Home
  |  Login
  HSG Mission

The Huntington Study Group (HSG) is dedicated to the mission: to give hope, provide opportunities, and seek treatments that make a difference to those affected by Huntington disease.

    
  News & Events

July 2014

The HSG is pleased to unveil our new logo, as featured on our website header! This new design represents a rejuvenation and reenergizing for our organization as we move forward into our 21st year. We hope you are as excited about the logo as we are!



Our friends at Help4HD are hosting their first-ever Symposium on Saturday, July 19 in Santa Maria, California. Featured keynotes will include our former chair, Ira Shoulson, and current chair, Ray Dorsey. CME and CE credits are being offered. Please see the following link for more information and to register. The event will also be streaming live here for those who are unable to attend in-person.



Some of our HSG team were fortunate enough to be present at the 29th Annual HDSA Convention in Louisville, Kentucky this past June- pictured here lighting our glow sticks in honor of the HD community at the Awards DInner and Gala. More information on the Convention can be found here.


June 2014

The HSG is pleased to announce the launch of a new clinical trial, Pride-HD! Pride-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN). Please see the Pride-HD page for more information.

May 2014

Maria De Rosa (Upstate NY HDSA President), Bill Lawler, Shari Kinel (HSG Executive Director)

Our Executive Director, Shari Kinel, was able to attend and participate in the 'Bill Lawler Huntingtons 5K' on Saturday, May 3 in Rochester, New York. Congratulations to all who participated in this successful event!


April 2014

The HSG, in collaboration with Teva Pharmaceutical Industries Ltd., is pleased to announce the start of an exciting new research opportunity: PRIDE-HD. This is a global Phase II trial evaluating pridopidine for HD. Further details of the trial can be found via the following press release. Please come back to visit the HSG website soon for further updates.


The HSG held a pivotal election this March, nominating new leadership to the HSG Executive Committee and Board of Directors. Please click here to see the exciting results.

  
  Save the Date for our Annual Event!


Registration to go live in Summer 2014: Stay Tuned!

  
  Dedication to Huntington Disease Research

The HSG fulfills its mission greatly through clinical research for HD. The HSG is comprised of clinical researchers worldwide who are dedicated to this mission. If you are a research site wishing to conduct HSG trials, learn more about becoming an HSG Site. If you wish to be contacted by the HSG about ongoing and upcoming research opportunities, please sign up for our Future Contact database.

Thank you for coming to visit our site and please continue to check back for frequent updates.

  
  Current HD Research Studies and Clinical Trials - Call 800-487-7671 to learn more

CURRENTLY ENROLLING

PRIDE-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN), with sponsorship by Teva Branded Pharmaceutical Products.


SD-809 ER (Auspex Pharmaceuticals)

SD-809 ER is an investigational study drug developed by Auspex Pharmaceuticals for the treatment of chorea. First-HD and ARC-HD are Phase III clinical trials that are currently enrolling. Both studies are evaluating SD-809 ER’s safety, tolerability and effectiveness in reducing chorea.

First-HD is designed for subjects who have not taken tetrabenazine in the past 6 months.

ARC-HD is for subjects who are currently taking tetrabenazine or those who participated in First-HD.

All participants are eligible for reimbursement of travel and lodging costs.  Participants in ARC-HD may be eligible to receive at no cost the study drug and medical supervision for up to 12 months.


  

CREST-E: A global, multi-center, clinical trial run in collaboration with Massachusetts General Hospital investigating the effects of creatine monohydrate on the progression of Huntington disease, led by Dr. Steven Hersch.


 

PREDICT-HD 2.0 - Observational research study for at-risk gene positive, pre-symptomatic, and gene negative tested individuals, with headquarters at the University of Iowa, under the leadership of Dr. Jane Paulsen.


On-going HSG Research Studies & Clinical Trials (ENROLLMENT COMPLETED)

Reach2HD - A clinical research trial investigating the effects of PBT2 on invidividuals with early to mid-stage Huntington disease, led by Ray Dorsey of Johns Hopkins University and Diana Rosas of Massachusetts General Hospital.


2CARE: A multi-center, randomized, double-blind, placebo-controlled trial led by Merit Cudkowicz, Michael McDermott, and Karl Kieburtz, assesing the effects of coenzyme Q10 on inviduals with mild-to-moderate Huntington disease.


PREQUEL: A clinical trial investigating the safety and tolerability of coenzyme Q10 for individuals with pre-manifest Huntington disease, led by Dr. Christopher Ross (John Hopkins University) and co-led by Dr. Kevin Biglan (University of Rochester).

  
  Donate to the HSG

The Huntington Study Group (HSG) welcomes financial contributions at any level in support of our research activities. Please click here for more information on how to contribute to the HSG and we THANK YOU for your generosity.